Experimental pill shows early promise for painful skin condition
NCT ID NCT05997277
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study tested the drug deucravacitinib against a placebo in people with moderate-to-severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. Only 7 people enrolled before the study was stopped early. The goal was to see if the drug could reduce inflammatory lesions over 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Deucravacitinib (a targeted oral medication that blocks a specific immune pathway)
- What this could lead to
- If it works, this could point toward a new oral treatment option for hidradenitis suppurativa, a painful skin condition.
- What could go wrong
- This is a very small, early pilot study that was terminated early with only 7 participants, so results are limited and may not be reliable. The drug may not prove effective or safe in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could childhood trauma fuel skin inflammation?
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New pill shows promise for controlling painful skin condition in long-term trial
- New shot could ease painful skin condition